NO983375L - Retroviral vektor og anvendelse derav i genterapi - Google Patents

Retroviral vektor og anvendelse derav i genterapi

Info

Publication number
NO983375L
NO983375L NO983375A NO983375A NO983375L NO 983375 L NO983375 L NO 983375L NO 983375 A NO983375 A NO 983375A NO 983375 A NO983375 A NO 983375A NO 983375 L NO983375 L NO 983375L
Authority
NO
Norway
Prior art keywords
retroviral vector
vector
gene therapy
reimplantation
transduced
Prior art date
Application number
NO983375A
Other languages
English (en)
Other versions
NO983375D0 (no
Inventor
Alan John Kingsman
Susan Mary Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601336.2A external-priority patent/GB9601336D0/en
Priority claimed from GBGB9620759.2A external-priority patent/GB9620759D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of NO983375D0 publication Critical patent/NO983375D0/no
Publication of NO983375L publication Critical patent/NO983375L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

DNA sekvenser for' å danne replikasjons-defekte retroviralé i vektorprodusentceller enten in vivo eller in vitro for reimplantasjon. Den retroviralé vektor omfatter minst ett heterologt gen og' funksjonelle env og gag-pol gener er fraværende fra vektoren slik at retrovirus-strukturelle proteiner ikke uttrykkes ved targetcellene infisert og transdusert med vektoren.
NO983375A 1996-01-23 1998-07-22 Retroviral vektor og anvendelse derav i genterapi NO983375L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9601336.2A GB9601336D0 (en) 1996-01-23 1996-01-23 Retrovirus
GBGB9620759.2A GB9620759D0 (en) 1996-10-04 1996-10-04 Retrovirus
PCT/GB1997/000210 WO1997027310A1 (en) 1996-01-23 1997-01-23 Retroviral vector and its use in gene therapy

Publications (2)

Publication Number Publication Date
NO983375D0 NO983375D0 (no) 1998-07-22
NO983375L true NO983375L (no) 1998-09-21

Family

ID=26308512

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983375A NO983375L (no) 1996-01-23 1998-07-22 Retroviral vektor og anvendelse derav i genterapi

Country Status (13)

Country Link
EP (1) EP0880594B1 (no)
JP (1) JP3535521B2 (no)
KR (1) KR19990087036A (no)
AT (1) ATE226638T1 (no)
AU (1) AU729934B2 (no)
CA (1) CA2243529A1 (no)
DE (1) DE69716581T2 (no)
DK (1) DK0880594T3 (no)
ES (1) ES2184059T3 (no)
NO (1) NO983375L (no)
NZ (1) NZ326429A (no)
PT (1) PT880594E (no)
WO (1) WO1997027310A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1078105B1 (en) * 1998-05-12 2004-11-24 Genecure LLC Replication defective hiv vaccine
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
EP1600511A4 (en) * 2003-02-19 2006-08-23 Dnavec Research Inc METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESS
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.

Also Published As

Publication number Publication date
EP0880594A1 (en) 1998-12-02
DE69716581D1 (de) 2002-11-28
NZ326429A (en) 2001-07-27
WO1997027310A1 (en) 1997-07-31
DK0880594T3 (da) 2002-12-16
ATE226638T1 (de) 2002-11-15
PT880594E (pt) 2003-03-31
NO983375D0 (no) 1998-07-22
JP3535521B2 (ja) 2004-06-07
DE69716581T2 (de) 2003-03-06
ES2184059T3 (es) 2003-04-01
CA2243529A1 (en) 1997-07-31
KR19990087036A (ko) 1999-12-15
AU729934B2 (en) 2001-02-15
JP2000500986A (ja) 2000-02-02
EP0880594B1 (en) 2002-10-23
AU1452297A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
DK0904392T3 (da) Retrovirale vektorer
ATE520783T1 (de) Lentivirale vektoren
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
DK0568537T3 (da) Genetisk modificering af endotelceller
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
NO983375L (no) Retroviral vektor og anvendelse derav i genterapi
DK0843731T3 (da) Adenovirusvektorer til genterapi
ATE323776T1 (de) Retrovirale vektoren zur expression in embryonalen zellen
PT1212428E (pt) Redireccionamento da expressao do gene gama 34.5 de herpes atraves de um promotor especifico de celulas e/ou especifico de tumores
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
ATE328100T1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
DK631387A (da) Virusvektor
MX9700555A (es) Procedimiento para la produccion de virus y vectores viricos.
Ballaun Charakterisierung der spezifischen Interaktion transregulatorischer Proteine humaner Retroviren (HIV-1, HTL-VI) mit ihren RNA-Zielsequenzen.
ATE412764T1 (de) Genetische transduktion von hämatopoietische vorläuferzellen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application